Transformation of MALT lymphoma to pure plasma cell histology following treatment with the anti-CD20 antibody rituximab
Authors:
- 1 November 2005
- journal article
- case report
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 46 (11) , 1645-1649
Abstract
Mucosa associated lymphoid tissue (MALT) lymphoma is a relatively common lymphoma arising from marginal-zone B-cells which are closely related to plasma cells. As opposed to the large majority of plasma cells, MALT lymphoma cells express CD20, and the anti-CD20 antibody rituximab has been reported as active treatment in patients with MALT lymphoma. We present a patient with MALT lymphoma involving stomach and lung which transformed to a pure plasma cell tumor after therapy with rituximab. This observation again supports the close association between the cell of origin of MALT lymphoma and plasma cells, suggesting that “plasmacytoma of the GI-tract” as anecdotally reported may in fact be a MALT lymphoma with extreme plasmacytic differentiation. In addition, our findings suggest that MALT lymphomas with plasmacytic differentiation might have a different 18F-FDG uptake as compared to classical MALT lymphoma.Keywords
This publication has 18 references indexed in Scilit:
- Clinical Activity of Rituximab in Gastric Marginal Zone Non-Hodgkin's Lymphoma Resistant to or Not Eligible for Anti–Helicobacter Pylori TherapyJournal of Clinical Oncology, 2005
- Anti‐CD20 monoclonal antibody therapy in relapsed MALT lymphoma of the conjunctivaEuropean Journal of Haematology, 2004
- Complete regression of primary gastric plasmacytoma following Helicobacter pylori eradicationAnnals of Hematology, 2004
- Rituximab-induced Remission of a Gastric MALT LymphomaLeukemia & Lymphoma, 2004
- Rituximab for Treatment of Advanced Extranodal Marginal Zone B Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue LymphomaOncology, 2003
- Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT typeBlood, 2003
- 18F-Fluorodeoxyglucose Positron Emission Tomography (18F-FDG-PET) for Staging and Follow-Up of Marginal Zone B-Cell LymphomaOncology, 2003
- Marginal-zone B cellsNature Reviews Immunology, 2002
- The World Health Organization Classification of Hematological Malignancies Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997Laboratory Investigation, 2000
- Immunoproliferative small intestinal disease: A study of 13 cases with alpha heavy-chain diseaseHistopathology, 1990